Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with HP Acthar Gel (R)

摘要

Introduction: Multiple sclerosis (MS) is an autoimmune disorder with large annual costs. This study evaluated utilization and costs for the management of MS relapses with H.P. Acthar (R) Gel (repository corticotropin injection; Acthar; Mallinckrodt) compared to receipt of plasmapheresis (PMP) or intravenous immunoglobulin (IVIG) among patients with MS who experienced multiple relapses.